Timothy W. Synold

TL;DR: It is shown that SXR also regulates drug efflux by activating expression of the gene MDR1, which encodes the protein P-glycoprotein (ABCB1) inCytochrome P450 3A4, an important mediator of drug catabolism that can be regulated by the steroid and xenobiotic receptor.

TL;DR: The topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts comprising four lines of adult colon adenocarcinoma, six childhood rhabdomyosarcomas from previously untreated patients as well as sublines selected in vivo for resistance to vincristine and melphalan, and three lines of childhood osteogenic sarcoma.

TL;DR: In vivo biodistribution studies demonstrated NSC retention of tumor tropism, even in mice pretreated with radiation or dexamethasone to mimic clinically relevant adjuvant therapies, and evaluated safety and toxicity after intracerebral administration of the NSCs in non–tumor-bearing and orthotopic glioma–bearing immunocompetent and immunodeficient mice.

TL;DR: It is demonstrated that the human immunodeficiency virus (HIV) protease inhibitor ritonavir binds SXR and activates its target genes, expanding the ligand specificity of SXR to include this unique chemical class whose pharmaceutical significance is expanding.

TL;DR: Concentrations of temozolomide in brain interstitium obtained by ICMD are consistent with published data obtained in a preclinical ICMD model, as well as from clinical studies of cerebrospinal fluid, however, the delayed time required to achieve maximum temozlomide concentrations in brain suggests that current chemoradiation regimens may be improved by administering temozoomide 2 to 3 hours before radiation.